Daniel C Norvell1, Jane B Shofer2, Sigvard T Hansen3, James Davitt4, John G Anderson5, Donald Bohay5, J Chris Coetzee6, John Maskill5, Michael Brage3, Michael Houghton7, William R Ledoux2,3,8, Bruce J Sangeorzan2,3. 1. 1 Spectrum Research, Tacoma, WA, USA. 2. 2 VA Puget Sound Health Care System, Seattle, WA, USA. 3. 3 Department of Orthopaedics and Sports Medicine, University of Washington, Seattle, WA, USA. 4. 4 Orthopedic + Fracture Specialists, Portland, OR, USA. 5. 5 Orthopaedic Associates of Michigan, Grand Rapids, MI, USA. 6. 6 Twin Cities Orthopedics, Edina, MN, USA. 7. 7 Orthopaedic & Spine Center of the Rockies, Fort Collins, CO, USA. 8. 8 Department of Mechanical Engineering, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: This study summarized the frequency and functional impact of adverse events (AEs) that occur after surgery for end-stage ankle arthritis (ESAA) to inform decision making. METHODS: This was a multisite prospective cohort study to compare ankle arthroplasty to ankle arthrodesis in the treatment of ESAA among 6 participating sites. We compared the risk and impact of nonankle AEs and ankle-specific AEs versus no AEs controlling for potential confounding factors, including operative procedure using multinomial logistic regression. We estimated differences in postoperative functional outcomes by AE occurrence using linear mixed effects regression. Among 517 patients who had surgery for ankle arthritis and completed the full baseline assessment, follow-up scores were available in 494 (95%) patients. RESULTS: There were a total of 628 reported AEs (477 in the arthroplasty group and 151 in the arthrodesis group). These occurred in 261 (63%) arthroplasty patients and 67 (65%) arthrodesis patients. There were 50 (8%) ankle-specific AEs. The risk of an ankle-specific AE was slightly higher in the arthrodesis group versus the arthroplasty group, odds ratio (OR) 1.84, 95% confidence interval (CI, 0.85, 3.98). The OR for the risk of non-ankle-specific AE versus no AE was 0.96, 95% CI (0.57, 1.61) for those receiving arthrodesis compared to arthroplasty. Compared to patients with no AEs, those experiencing ankle-specific AEs had significantly less improvement in Foot and Ankle Ability Measure Sports and activities of daily living (ADL) subscores and worst pain outcomes; however, both groups improved significantly in all measures except mental health. CONCLUSIONS: Ankle-specific AEs were infrequent and only weakly associated with operative procedure. Although patients improved in all functional outcomes except mental health, regardless of AE occurrence, ankle-specific AEs negatively impacted patient improvement compared to those with no AEs or a nonankle AE. The logistical effort and cost of tracking nonankle AEs does not seem to be justified. LEVEL OF EVIDENCE: Level II, prospective comparative study.
BACKGROUND: This study summarized the frequency and functional impact of adverse events (AEs) that occur after surgery for end-stage ankle arthritis (ESAA) to inform decision making. METHODS: This was a multisite prospective cohort study to compare ankle arthroplasty to ankle arthrodesis in the treatment of ESAA among 6 participating sites. We compared the risk and impact of nonankle AEs and ankle-specific AEs versus no AEs controlling for potential confounding factors, including operative procedure using multinomial logistic regression. We estimated differences in postoperative functional outcomes by AE occurrence using linear mixed effects regression. Among 517 patients who had surgery for ankle arthritis and completed the full baseline assessment, follow-up scores were available in 494 (95%) patients. RESULTS: There were a total of 628 reported AEs (477 in the arthroplasty group and 151 in the arthrodesis group). These occurred in 261 (63%) arthroplasty patients and 67 (65%) arthrodesis patients. There were 50 (8%) ankle-specific AEs. The risk of an ankle-specific AE was slightly higher in the arthrodesis group versus the arthroplasty group, odds ratio (OR) 1.84, 95% confidence interval (CI, 0.85, 3.98). The OR for the risk of non-ankle-specific AE versus no AE was 0.96, 95% CI (0.57, 1.61) for those receiving arthrodesis compared to arthroplasty. Compared to patients with no AEs, those experiencing ankle-specific AEs had significantly less improvement in Foot and Ankle Ability Measure Sports and activities of daily living (ADL) subscores and worst pain outcomes; however, both groups improved significantly in all measures except mental health. CONCLUSIONS: Ankle-specific AEs were infrequent and only weakly associated with operative procedure. Although patients improved in all functional outcomes except mental health, regardless of AE occurrence, ankle-specific AEs negatively impacted patient improvement compared to those with no AEs or a nonankle AE. The logistical effort and cost of tracking nonankle AEs does not seem to be justified. LEVEL OF EVIDENCE: Level II, prospective comparative study.
Authors: Marc L Berger; Nancy Dreyer; Fred Anderson; Adrian Towse; Art Sedrakyan; Sharon-Lise Normand Journal: Value Health Date: 2012 Mar-Apr Impact factor: 5.725
Authors: Steven D Culler; David S Jevsevar; Kevin G Shea; Kevin J McGuire; Kimberly K Wright; April W Simon Journal: J Arthroplasty Date: 2015-08-01 Impact factor: 4.757
Authors: John Concato; Elizabeth V Lawler; Robert A Lew; J Michael Gaziano; Mihaela Aslan; Grant D Huang Journal: Am J Med Date: 2010-12 Impact factor: 4.965
Authors: Robroy L Martin; James J Irrgang; Ray G Burdett; Stephen F Conti; Jessie M Van Swearingen Journal: Foot Ankle Int Date: 2005-11 Impact factor: 2.827
Authors: Arjun S Sebastian; Stephanie F Polites; Amy E Glasgow; Elizabeth B Habermann; Robert R Cima; Sanjeev Kakar Journal: J Hand Surg Am Date: 2016-11-23 Impact factor: 2.230
Authors: Daniel C Norvell; William R Ledoux; Jane B Shofer; Sigvard T Hansen; James Davitt; John G Anderson; Donald Bohay; J Chris Coetzee; John Maskill; Michael Brage; Michael Houghton; Bruce J Sangeorzan Journal: J Bone Joint Surg Am Date: 2019-08-21 Impact factor: 5.284
Authors: Sultan Ayyadah Alanazi; Bill Vicenzino; Christiaan J A van Bergen; David J Hunter; Erik A Wikstrom; Hylton B Menz; Yvonne M Golightly; Michelle D Smith Journal: Trials Date: 2022-09-05 Impact factor: 2.728